

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10623036	
	Filing Date		2003-07-18	
	First Named Inventor	Willem P.C. Stemmer		
	Art Unit	1637		
	Examiner Name	Samuel C. Woolwine		
	Attorney Docket Number	0100.227US		

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	9319172	WO	A1	1993-09-30	Johnson et al.		<input type="checkbox"/>
	2	9324635	WO	A1	1993-12-09	Bennett et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS								
---------------------------------	--	--	--	--	--	--	--	--

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10623036
Filing Date	2003-07-18
First Named Inventor	Willem P.C. Stemmer
Art Unit	1637
Examiner Name	Samuel C. Woolwine
Attorney Docket Number	0100.227US

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	Auron et al., "Nucleotide sequence of human monocyte interleukin 1 precursor cDNA," Proc. Natl. Acad. Sci. 81:7907-7911 (1984)	<input type="checkbox"/>
	2	Berlin et al., "Cloning, nucleotide sequencing and expression of cDNAs encoding mouse urokinase-type plasminogen activator," European J. Biochemistry 148:225-232 (1985)	<input type="checkbox"/>
	3	Carter, Paul et al., "Antibody engineering using very long template-assembled oligonucleotides," Methods: A Companion to Methods in Enzymology 3(3): 183-192 (1991)	<input type="checkbox"/>
	4	McPherson, M.J., "Recombination and mutagenesis of DNA sequences using PCR," Chapter 11 from Directed Mutagenesis A Practical Approach, eds. D. Rickwood and B.D. Hames, IRL Press at Oxford University Press, New York, pages 217-257	<input type="checkbox"/>
	5	Paabo, S. et al., "Ancient DNA and the polymerase chain reaction," The Journal of Biological Chemistry 264 (17):9709-9712 (1989)	<input type="checkbox"/>
	6	Riccio et al., "The human urokinase-plasminogen activator gene and its promoter," Nucleic Acid Res. 13:2759-2771 (1985)	<input type="checkbox"/>
	7	Soderlind, E. et al., "Domain libraries: Synthetic diversity for de novo design of antibody V-regions," Gene 160:269-272 (1995)	<input type="checkbox"/>
	8	Stahl, S. et al., "Solid-phase gene assembly of constructs derived from the plasmodium falciparum malaria blood-stage antigen Ag332," BioTechniques 14(3):424-434 (1993)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10623036
Filing Date	2003-07-18
First Named Inventor	Willem P.C. Stemmer
Art Unit	1637
Examiner Name	Samuel C. Woolwine
Attorney Docket Number	0100.227US

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10623036
Filing Date	2003-07-18
First Named Inventor	Willem P.C. Stemmer
Art Unit	1637
Examiner Name	Samuel C. Woolwine
Attorney Docket Number	0100.227US

**CERTIFICATION STATEMENT**

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

**OR**

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).


☐ See attached certification statement.

☒ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☐ None

**SIGNATURE**

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature		Date (YYYY-MM-DD)	2007-04-24
Name/Print	SHARON M. FUJITA	Registration Number	38,459

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**